{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:17:03Z","timestamp":1761862623787},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Dermatology"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.yadr.2006.07.001","type":"journal-article","created":{"date-parts":[[2006,12,23]],"date-time":"2006-12-23T12:14:17Z","timestamp":1166876057000},"page":"101-124","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Systemic Antifungal Agents: An Update of Established and New Therapies"],"prefix":"10.1016","volume":"22","author":[{"given":"Daniel S.","family":"Loo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yadr.2006.07.001_bib1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1046\/j.1365-2133.2003.05728.x","article-title":"Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis","volume":"150","author":"Gupta","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.yadr.2006.07.001_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1046\/j.1365-2133.2001.04378.x","article-title":"Long-term efficacy of antifungals in toenail onychomycosis: a critical review","volume":"145","author":"Cribier","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.yadr.2006.07.001_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1439-0507.1998.tb00379.x","article-title":"Long-term post-treatment follow-up of onychomycosis treated with terbinafine: a multicentre trial","volume":"41","author":"T\u00f6r\u00f6k","year":"1998","journal-title":"Mycoses"},{"key":"10.1016\/j.yadr.2006.07.001_bib4","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/bmj.317.7165.1084","article-title":"Successful treatment of toenail mycosis with terbinafine and itraconazole gives long term benefits","volume":"317","author":"Bra\u00a8utigam","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.yadr.2006.07.001_bib5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000017990","article-title":"Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up","volume":"197","author":"Tosti","year":"1998","journal-title":"Dermatology"},{"issue":"6 Pt 2","key":"10.1016\/j.yadr.2006.07.001_bib6","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S0190-9622(98)70490-6","article-title":"Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail","volume":"38","author":"Scher","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.yadr.2006.07.001_bib7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/archderm.138.3.353","article-title":"Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study","volume":"138","author":"Sigurgeirsson","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.yadr.2006.07.001_bib8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2230.1995.tb01353.x","article-title":"Nail incorporation kinetics of terbinafine in onychomycosis patients","volume":"20","author":"Schatz","year":"1995","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.yadr.2006.07.001_bib9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1346-8138.1996.tb04009.x","article-title":"Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach","volume":"23","author":"Alpsoy","year":"1996","journal-title":"J Dermatol"},{"key":"10.1016\/j.yadr.2006.07.001_bib10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0190-9622(96)80057-0","article-title":"Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy","volume":"34","author":"Tosti","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.yadr.2006.07.001_bib11","doi-asserted-by":"crossref","DOI":"10.1067\/mjd.2001.110644","article-title":"Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis","author":"Gupta","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.yadr.2006.07.001_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2005.04.055","article-title":"Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial","author":"Warshaw","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"2 Pt 1","key":"10.1016\/j.yadr.2006.07.001_bib13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1067\/mjd.2000.104794","article-title":"Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter canadian survey of 15,000 patients","volume":"43","author":"Gupta","year":"2000","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.yadr.2006.07.001_bib14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1439-0507.1995.tb00075.x","article-title":"Aetiology of onychomycosis in Al Ain, United Arab Emirates","volume":"38","author":"Nsanze","year":"1995","journal-title":"Mycoses"},{"key":"10.1016\/j.yadr.2006.07.001_bib15","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1046\/j.1468-3083.2001.00206.x","article-title":"Itraconazole pulse therapy for the treatment of Candida onychomycosis","volume":"15","author":"Gupta","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.yadr.2006.07.001_bib16","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1046\/j.1365-4362.2001.01204.x","article-title":"Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis","volume":"40","author":"Lebwohl","year":"2001","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.yadr.2006.07.001_bib17","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0190-9622(96)90120-6","article-title":"Treatment of Candida nail infection with terbinafine","volume":"35","author":"Segal","year":"1996","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.yadr.2006.07.001_bib18","first-page":"258","article-title":"Open label trial of the efficacy and tolerability of Lamisil (Terbinafine) 500 mg once daily in the treatment of onychomycosis due to candida","volume":"46","author":"Zaidi","year":"1996","journal-title":"J\u00a0Pak\u00a0Med Assoc"},{"issue":"Suppl 65","key":"10.1016\/j.yadr.2006.07.001_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2133.149.s65.5.x","article-title":"Onychomycosis in clinical practice: factors contributing to recurrence","volume":"149","author":"Scher","year":"2003","journal-title":"Br\u00a0J Dermatol"},{"key":"10.1016\/j.yadr.2006.07.001_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00006454-199902000-00029","article-title":"The evolving role of itraconazole, fluconazole and terbinafine in the treatment of tinea capitis","volume":"18","author":"Friedlander","year":"1999","journal-title":"Pediatr Infect Dis J"},{"issue":"1 Pt 1","key":"10.1016\/j.yadr.2006.07.001_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0190-9622(00)90001-X","article-title":"Tinea capitis: a current perspective","volume":"42","author":"Elewski","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.yadr.2006.07.001_bib22","series-title":"Physician's desk reference","year":"2005"},{"key":"10.1016\/j.yadr.2006.07.001_bib23","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1046\/j.1365-2133.2002.04744.x","article-title":"A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species","volume":"146","author":"Lipozencic","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.yadr.2006.07.001_bib24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1046\/j.1525-1470.2001.01978.x","article-title":"Therapeutic options for the treatment of tinea capitis caused by Trichophyton species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole","volume":"18","author":"Gupta","year":"2001","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.yadr.2006.07.001_bib25","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.jaad.2005.07.028","article-title":"A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis","volume":"53","author":"Foster","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.yadr.2006.07.001_bib26","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1542\/peds.109.4.602","article-title":"Terbinafine in the treatment of Trichophyton tinea capitis: a randomized, double-blind, parallel-group, duration-finding study","volume":"109","author":"Friedlander","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.yadr.2006.07.001_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1468-3083.2004.00854.x","article-title":"Efficacy and tolerability of 8 weeks' treatment with terbinafine in children with tinea capitis caused by Microsporum canis: a comparison of three doses","volume":"18","author":"Devliotou-Panagiotidou","year":"2004","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.yadr.2006.07.001_bib28","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1365-2230.2004.01493.x","article-title":"Treatment of Microsporum spp. tinea capitis with pulsed oral terbinafine","volume":"29","author":"Ungpakorn","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.yadr.2006.07.001_bib29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.0736-8046.2004.21419.x","article-title":"Itraconazole in the treatment of tinea capitis caused by Microsporum canis: experience in a large cohort","volume":"21","author":"Ginter-Hanselmayer","year":"2004","journal-title":"Pediatr Dermatol"},{"issue":"2 Pt 1","key":"10.1016\/j.yadr.2006.07.001_bib30","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0190-9622(97)80141-7","article-title":"Fluconazole for the treatment of tinea capitis in children","volume":"37","author":"Solomon","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.yadr.2006.07.001_bib31","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1365-2133.1999.02981.x","article-title":"Intermittent short duration therapy with fluconazole is effective for tinea capitis","volume":"141","author":"Gupta","year":"1999","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.yadr.2006.07.001_bib32","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1046\/j.1365-4362.1998.00584.x","article-title":"Fluconazole in the treatment of tinea capitis","volume":"37","author":"Montero-Gei","year":"1998","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.yadr.2006.07.001_bib33","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1046\/j.1365-2133.2000.03479.x","article-title":"Once weekly fluconazole is effective in the treatment of tinea capitis: a prospective, multicentre study","volume":"142","author":"Gupta","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.yadr.2006.07.001_bib34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00006454-198701000-00012","article-title":"Epidemiology and treatment of tinea capitis: ketoconazole vs. griseofulvin","volume":"6","author":"Gan","year":"1987","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.yadr.2006.07.001_bib35","series-title":"Terbinafine in treatment of superficial fungal infections. International congress series","first-page":"35","article-title":"A randomized double-blind trial of the efficacy and tolerability of terbinafine once daily compared to griseofulvin once daily in the treatment of tinea capitis","author":"Alvi","year":"1993"},{"key":"10.1016\/j.yadr.2006.07.001_bib36","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-4362.1994.tb01525.x","article-title":"Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized study in children","volume":"33","author":"Lopez-Gomez","year":"1994","journal-title":"Int J Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.yadr.2006.07.001_bib37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1470-9465.2004.00838.x","article-title":"Voriconazole-a new therapeutic agent with an extended spectrum of antifungal activity","volume":"10","author":"Donnelly","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.yadr.2006.07.001_bib38","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yadr.2006.07.001_bib39","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1086\/322653","article-title":"A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients","volume":"33","author":"Ally","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.yadr.2006.07.001_bib40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/13693780410001731583","article-title":"In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species","volume":"43","author":"Gupta","year":"2005","journal-title":"Med Mycol"},{"key":"10.1016\/j.yadr.2006.07.001_bib41","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1086\/428780","article-title":"Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases","volume":"191","author":"Kontoyiannis","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.yadr.2006.07.001_bib42","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1128\/AAC.49.12.5136-5138.2005","article-title":"In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi","volume":"49","author":"Cuenca-Estrella","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.yadr.2006.07.001_bib43","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1128\/AAC.48.8.3107-3111.2004","article-title":"In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates","volume":"48","author":"Cuenca-Estrella","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.yadr.2006.07.001_bib44","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1468-3083.2005.01212.x","article-title":"A phase I\/II randomized, double-blind, placebo-controlled,\u00a0dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis","volume":"19","author":"Gupta","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.yadr.2006.07.001_bib45","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.0007-0963.2004.05878.x","article-title":"Cutaneous infection by Fusarium: successful treatment with oral voriconazole","volume":"150","author":"Guimera-Martin-Neda","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.yadr.2006.07.001_bib46","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1365-2133.2005.06534.x","article-title":"Madurella mycetomatis mycetoma treated successfully with oral voriconazole","volume":"152","author":"Lacroix","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.yadr.2006.07.001_bib47","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1046\/j.1469-0691.2003.00596.x","article-title":"Two cases of subcutaneous Scedosporium apiospermum infection treated with voriconazole","volume":"9","author":"Bosma","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.yadr.2006.07.001_bib48","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1128\/JCM.43.2.973-977.2005","article-title":"Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy","volume":"43","author":"Schaenman","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.yadr.2006.07.001_bib49","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1086\/380840","article-title":"Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera","volume":"38","author":"Negroni","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.yadr.2006.07.001_bib50","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yadr.2006.07.001_bib51","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0002-9343(02)01191-9","article-title":"A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis","volume":"113","author":"Villanueva","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.yadr.2006.07.001_bib52","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00126334-200210010-00009","article-title":"Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole","volume":"31","author":"Kartsonis","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.yadr.2006.07.001_bib53","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yadr.2006.07.001_bib54","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy","volume":"39","author":"Maertens","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.yadr.2006.07.001_bib55","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/00365540410020406","article-title":"A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan","volume":"36","author":"Kohno","year":"2004","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.yadr.2006.07.001_bib56","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1086\/423377","article-title":"A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients","volume":"39","author":"de Wet","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.yadr.2006.07.001_bib57","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2036.2004.02083.x","article-title":"Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent","volume":"20","author":"Pettengell","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.yadr.2006.07.001_bib58","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.yadr.2006.07.001_bib59","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1128\/AAC.48.6.2021-2024.2004","article-title":"Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia","volume":"48","author":"Krause","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.yadr.2006.07.001_bib60","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/423378","article-title":"A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis","volume":"39","author":"Krause","year":"2004","journal-title":"Clin Infect Dis"}],"container-title":["Advances in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882088006000022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882088006000022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T15:51:25Z","timestamp":1547135485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882088006000022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":60,"alternative-id":["S0882088006000022"],"URL":"https:\/\/doi.org\/10.1016\/j.yadr.2006.07.001","relation":{},"ISSN":["0882-0880"],"issn-type":[{"value":"0882-0880","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}